Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilmer

Showing results (781-790 of 825) with videos related to

Pageof 83
Sort By:
Environmental Research|June 24, 2023
The bioengineered and multifunctional nanoparticles in pancreatic cancer therapy: Bioresponisive nanostructures, phototherapy and targeted drug deliveryMohamed J Saadh, Hala Baher, Yuanji Li, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2003
Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolinesMicheal D Gaul, Yu Guo, Karen Affleck, et al.
The Journal of Pathology. Clinical Research|June 30, 2018
Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancerCamilla Coulson-Gilmer, Matthew P Humphries, Sreekumar Sundara Rajan, et al.
AIDS Care|July 3, 2024
Lifetime HIV testing among three samples of adults with histories of incarceration in Southern CaliforniaVictoria D Ojeda, Melissa B Jaeger, Sarah Hiller-Venegas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial dataJulian R Molina, Scott H Kaufmann, Joel M Reid, et al.
Annals of the Rheumatic Diseases|April 7, 2007
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite studyDaniel E Furst, Norman Gaylis, Vance Bray, et al.
Nature Cancer|February 5, 2022
An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognosticationOlivier Morin, Martin Vallières, Steve Braunstein, et al.
International Journal of Radiation Oncology, Biology, Physics|November 24, 2023
Predicting the Effect of Proton Beam Therapy Technology on Pulmonary Toxicities for Patients With Locally Advanced Lung Cancer Enrolled in the Proton Collaborative Group Prospective Clinical TrialGilmer Valdes, Jessica Scholey, Tomi F Nano, et al.
Plos One|October 10, 2022
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Plos One|March 22, 2013
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Pageof 83

Showing results (781-790 of 825) with videos related to

Sort By:
Pageof 83
Environmental Research|June 24, 2023
The bioengineered and multifunctional nanoparticles in pancreatic cancer therapy: Bioresponisive nanostructures, phototherapy and targeted drug deliveryMohamed J Saadh, Hala Baher, Yuanji Li, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2003
Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolinesMicheal D Gaul, Yu Guo, Karen Affleck, et al.
The Journal of Pathology. Clinical Research|June 30, 2018
Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancerCamilla Coulson-Gilmer, Matthew P Humphries, Sreekumar Sundara Rajan, et al.
AIDS Care|July 3, 2024
Lifetime HIV testing among three samples of adults with histories of incarceration in Southern CaliforniaVictoria D Ojeda, Melissa B Jaeger, Sarah Hiller-Venegas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2008
Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial dataJulian R Molina, Scott H Kaufmann, Joel M Reid, et al.
Annals of the Rheumatic Diseases|April 7, 2007
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite studyDaniel E Furst, Norman Gaylis, Vance Bray, et al.
Nature Cancer|February 5, 2022
An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognosticationOlivier Morin, Martin Vallières, Steve Braunstein, et al.
International Journal of Radiation Oncology, Biology, Physics|November 24, 2023
Predicting the Effect of Proton Beam Therapy Technology on Pulmonary Toxicities for Patients With Locally Advanced Lung Cancer Enrolled in the Proton Collaborative Group Prospective Clinical TrialGilmer Valdes, Jessica Scholey, Tomi F Nano, et al.
Plos One|October 10, 2022
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric CancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Plos One|March 22, 2013
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancerManish A Shah, Zev A Wainberg, Daniel V T Catenacci, et al.
Pageof 83